| Structural insight into the dual function of LbpB in mediating Neisserial pathogenesis R Yadav, S Govindan, C Daczkowski, A Mesecar, S Chakravarthy, ... Elife 10, e71683, 2021 | 12 | 2021 |
| Beyond lipids: Novel mechanisms for parenteral nutrition–associated liver disease BE Wichman, J Nilson, S Govindan, A Chen, A Jain, V Arun, J Derdoy, ... Nutrition in Clinical Practice 37 (2), 265-273, 2022 | 11 | 2022 |
| Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide F Riekhof, Y Yan, CL Bennett, KM Sanfilippo, KR Carson, SH Chang, ... Clinical Genitourinary Cancer 22 (2), 18-26. e3, 2024 | 9 | 2024 |
| Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide S Govindan, N Cheranda, F Riekhof, S Luo, MW Schoen The Prostate 84 (3), 245-253, 2024 | 5 | 2024 |
| Survival of patients with metastatic prostate cancer and comorbid obesity. N Cheranda, S Luo, F Riekhof, S Govindan, KM Sanfilippo, MW Schoen Journal of Clinical Oncology 40 (6_suppl), 116-116, 2022 | 4 | 2022 |
| Treatment patterns and survival among veterans with de novo metastatic hormone-sensitive prostate cancer MW Schoen, J Doherty, D Eaton, S Khan, D Candelieri, N Fedele, P Baxi, ... JAMA Network Open 8 (5), e259433-e259433, 2025 | 1 | 2025 |
| Hospitalizations and common infections among veterans treated for metastatic prostate cancer. F Riekhof, S Luo, N Cheranda, S Govindan, KM Sanfilippo, MW Schoen Journal of Clinical Oncology 40 (6_suppl), 92-92, 2022 | 1 | 2022 |
| Treatment outcomes of patients with metastatic prostate cancer and co-morbid diabetes mellitus. S Govindan, S Luo, N Cheranda, F Riekhof, MW Schoen Journal of Clinical Oncology 40 (6_suppl), 113-113, 2022 | 1 | 2022 |
| A case of autoimmune glial fibrillary acidic protein astrocytopathy with concurrent renal cell carcinoma K Arrabothu, S Govindan, W Rodriguez, C Tapia, RL White III Neuroimmunology Reports 6, 100226, 2024 | | 2024 |
| Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease. MW Schoen, RD Etzioni, S Luo, D Candelieri, N Fedele, P Baxi, C Pickett, ... Journal of Clinical Oncology 42 (16_suppl), 5092-5092, 2024 | | 2024 |
| Clinical characteristics and outcomes of veterans with metastatic hormone-sensitive prostate cancer (mHSPC) based on volume of disease and site of metastases. K Stackable, C Pickett, F Riekhof, N Fedele, P Baxi, K Ingram, ... Journal of Clinical Oncology 42 (16_suppl), e17083-e17083, 2024 | | 2024 |
| A Case of Seropositive Autoimmune Glial Fibrillary Acidic Protein Encephalitis with Renal Cell Carcinoma (P4-5.010) K Arrabothu, S Govindan, W Rodriguez, S Xie, C Tapia, R White Neurology 100 (17_supplement_2), 4314, 2023 | | 2023 |
| Survival and hemoglobin A1c in metastatic castrate resistant prostate cancer. S Govindan, N Cheranda, S Luo, F Riekhof, MW Schoen Journal of Clinical Oncology 41 (6_suppl), 75-75, 2023 | | 2023 |
| Structural insight into dual function of Neisserial lactoferrin binding protein B R Yadav, S Govindan, S Chakravarthy, CM Daczkowski, AD Mesecar, ... ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES 77, A181-A181, 2021 | | 2021 |
| Neuroimmunology Reports K Arrabothu, S Govindan, W Rodriguez, C Tapia, RL White III | | |
